BBSRC invests £48m in Babraham Institute to advance lifelong health research
The funding will help to support research across epigenetics, immunology and cell signalling
Read More
Tag: Babraham Institute
PlaqueTec and Babraham Institute partner for treatment of coronary heart disease
CAD is responsible for around 68,000 deaths per year in the UK
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
